ClinicalTrials.gg
CompletedNCT05762471Updated Apr 25, 2024

Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

A Phase 1/2 interventional study of GSBR-1290 and Placebo in Overweight or Obesity and Type2 Diabetes Mellitus, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-25.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (part of Structure Therapeutics) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV) and Type 2 Diabetes Mellitus on Metformin (T2DM) This study includes 5 planned cohorts. Participants will receive multiple-ascending doses of GSBR-1290 or Placebo from Day 1 to Day 84

02

Conditions studied

  • Overweight or Obesity
  • Type2 Diabetes Mellitus

Browse trials for

03

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 142 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria cohorts 1-4:

  1. Provided evidence of a signed consent
  2. Age ≥ 18 and ≤ 75 years
  3. Healthy overweight/obese adult men and women with ≥ 27 and ≤ 40 kg/m2
  4. No nicotine use
  5. Have a suitable venous access for blood sampling

Inclusion Criteria cohort 5:

  1. Men and women with T2DM of ≥6 months duration
  2. Age ≥ 18 and ≤ 75 years
  3. BMI ≥ 27 and ≤ 40 kg/m2
  4. Treated with stable doses of ≥500 mg of metformin with a duration ≥6 months and at stable doses for ≥2 months with a screening ≥7.0% and ≤10.5%.

Exclusion Criteria:

  1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within the major 3 months
  2. A sitting BP after resting for 5 minutes > 160mm Hg systolic or > 100 mm Hg diastolic or an apical pulse rate \<50 or >100 beats per minute.
  3. Evidence of abnormality on the screening visit , or a history of known arrhythmia or prolonged pr prolonged QRS interval
  4. Liver function test results elevated > 2.0-fold above the for gamma glutamyl transferase, alkaline phosphatase, or alanine aminotransferase. above the ULN
  5. Estimated \< 60mL/min/1.73 m2 body surface area
  6. Known to any of the study drug ingredients
  7. Any other condition or prior therapy that would make the participant unsuitable for this study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks

    Drug: GSBR-1290 · Drug: Placebo

  • Experimental
    Cohort 2

    Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks

    Drug: GSBR-1290 · Drug: Placebo

  • Experimental
    Cohort 3

    Patients will receive once daily doses of study drug (GSBR-1290 or Placebo) for a total of 4 weeks

    Drug: GSBR-1290 · Drug: Placebo

  • Experimental
    Cohort 4

    HOV participants (Cohort 4) will receive multiple-ascending doses of GSBR-1290 or placebo for a total of 12 weeks

    Drug: GSBR-1290 · Drug: Placebo

  • Experimental
    Cohort 5

    Participants with T2DM(Cohort 5) will be randomized to placebo, low-dose, or high-dose arms. Participants in the low-dose, high-dose or placebo arms will receive multiple-ascending doses for 12 weeks

    Drug: GSBR-1290 · Drug: Placebo

Interventions

  • Patients will receive GSBR-1290 or matching Placebo

  • DrugPlacebo

    Patients will receive GSBR-1290 or matching Placebo

06

What researchers measure

Primary outcomes

  1. Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM

    Time frame: 42 days

Secondary outcomes

  1. Analysis of Cmax at specified timepoints predose and postdose to calculate PK parameters

    Time frame: 31 days

  2. Analysis of Tmax at specified timepoints predose and postdose to calculate PK parameters

    Time frame: 31 days

  3. Analysis of AUC at specified timepoints predose and postdose to calculate PK parameters

    Time frame: 31 days

  4. Identification of GSBR-1290 metabolites following oral administration of multiple doses in plasma

    Time frame: 31 days

07

Study locations

4 sites
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • ProSciento, Inc
    Chula Vista, California 91911, United States
  • QPS Miami Research Associates
    Miami, Florida 33143, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol

Time frame: Data sharing requests will be considered beginning 36 months after the study publication (manuscript accepted for publication) and either 1) the product have been granted marketing authorization in at least two regulatory jurisdictions, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Researchers will submit a request containing the research objectives, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). Structure Therapeutics does not grant external requests for individual de-identified patient data for the following purposes: re-evaluating safety and efficacy end points already addressed in the product labelling, assessing safety or efficacy for an indication in current development Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a panel of external advisors. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Apr 2024, 15 months.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2023
First posted
Mar 9, 2023
StartActual
Jan 9, 2023
Primary completionActual
Apr 11, 2024
CompletionActual
Apr 11, 2024
Last update
Apr 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05762471
Responsible party
Sponsor
First posted
Mar 9, 2023
Start date
Jan 9, 2023
Primary completion
Apr 11, 2024
Completion
Apr 11, 2024
Last update
Apr 25, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aleniglipron

Start the discussion